Androgen Antagonists

"Androgen Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Compounds which inhibit or antagonize the biosynthesis or actions of androgens.

Descriptor ID	D000726
MeSH Number(s)	D06.347.065 D27.505.696.399.450.065
Concept/Terms	Androgen Antagonists Androgen Antagonists Antagonists, Androgen Antiandrogens Anti-Androgen Effect Anti-Androgen Effect Anti Androgen Effect Effect, Anti-Androgen Antiandrogen Effect Effect, Antiandrogen Antiandrogen Effects Effects, Antiandrogen Anti-Androgen Effects Anti Androgen Effects Effects, Anti-Androgen

Below are MeSH descriptors whose meaning is more general than "Androgen Antagonists".

Chemicals and Drugs [D]
Hormones, Hormone Substitutes, and Hormone Antagonists [D06]
Hormone Antagonists [D06.347]
Androgen Antagonists [D06.347.065]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Physiological Effects of Drugs [D27.505.696]
Hormones, Hormone Substitutes, and Hormone Antagonists [D27.505.696.399]
Hormone Antagonists [D27.505.696.399.450]
Androgen Antagonists [D27.505.696.399.450.065]

Below are MeSH descriptors whose meaning is related to "Androgen Antagonists".

Below are MeSH descriptors whose meaning is more specific than "Androgen Antagonists".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Androgen Antagonists" by people in this website by year, and whether "Androgen Antagonists" was a major or minor topic of these publications.

Bar chart showing 26 publications over 16 distinct years, with a maximum of 3 publications in 2006 and 2014 and 2022 and 2023

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1998	0	1	1
2001	0	1	1
2003	0	1	1
2005	1	0	1
2006	2	1	3
2007	1	0	1
2008	1	1	2
2011	0	1	1
2012	0	1	1
2014	1	2	3
2015	1	0	1
2016	0	1	1
2017	1	0	1
2018	1	1	2
2022	0	3	3
2023	0	3	3

Below are the most recent publications written about "Androgen Antagonists" by people in Profiles.

Khan AF, Karami S, Peidl AS, Waiters KD, Babajide MF, Bawa-Khalfe T. Androgen Receptor in Hormone Receptor-Positive Breast Cancer. Int J Mol Sci. 2023 Dec 29; 25(1).

View in: PubMed
Sutera P, Shetty AC, Song Y, Hodges T, Hoang T, Rana Z, Pienta K, Feng F, Song DY, DeWeese T, Gillessen S, Sweeney C, James N, Attard G, Deek M, Tran PT. Identification of a Predictive Genomic Biomarker for Prostate-directed Therapy in Synchronous Low-volume Metastatic Castration-sensitive Prostate Cancer. Eur Urol Oncol. 2024 Apr; 7(2):241-247.

View in: PubMed
Gaynor AM, Flaherty KR, Root JC, Salas-Ramirez KY, Scott JM, Nelson CJ. Exercise Associated with Cognitive Function in Older Men with Prostate Cancer Undergoing Androgen Deprivation Therapy. Int J Behav Med. 2023 Dec; 30(6):924-929.

View in: PubMed
Andrews JR, Ahmed ME, Sharma V, Britton C, Stish B, Phillips R, Kendi AT, Joshi VB, Sood A, Tollefson MK, Boorjian SA, Karnes RJ, Kwon ED. Metastasis-directed Therapy Without Androgen Deprivation Therapy in Solitary Oligorecurrent Prostate Cancer. J Urol. 2022 12; 208(6):1240-1249.

View in: PubMed
McManus JM, Vargas R, Bazeley PS, Schumacher FR, Sharifi N. Association Between Adrenal-Restrictive HSD3B1 Inheritance and Hormone-Independent Subtypes of Endometrial and Breast Cancer. JNCI Cancer Spectr. 2022 09 01; 6(5).

View in: PubMed
Sood A, Zhang LT, Keeley J, Butaney M, Stricker M, Andrews JR, Grauer R, Peabody JO, Rogers CG, Menon M, Abdollah F. Optimizing anti-androgen treatment use among men with pathologic lymph-node positive prostate cancer treated with radical prostatectomy: the importance of postoperative PSA kinetics. Prostate Cancer Prostatic Dis. 2024 Mar; 27(1):58-64.

View in: PubMed
Xie Y, Fan H, Lu W, Yang Q, Nurkesh A, Yeleussizov T, Maipas A, Lu J, Manarbek L, Chen Z, Benassi E. Nuclear MET requires ARF and is inhibited by carbon nanodots through binding to phospho-tyrosine in prostate cancer. Oncogene. 2019 04; 38(16):2967-2983.

View in: PubMed
George A, Raji I, Cinar B, Kucuk O, Oyelere AK. Design, synthesis, and evaluation of the antiproliferative activity of hydantoin-derived antiandrogen-genistein conjugates. Bioorg Med Chem. 2018 05 01; 26(8):1481-1487.

View in: PubMed
Hamilton N, Austin D, M?rquez-Garb?n D, Sanchez R, Chau B, Foos K, Wu Y, Vadgama J, Pietras R. Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer. Int J Mol Sci. 2017 Nov 02; 18(11).

View in: PubMed
Khurana N, Talwar S, Chandra PK, Sharma P, Abdel-Mageed AB, Mondal D, Sikka SC. Sulforaphane increases the efficacy of anti-androgens by rapidly decreasing androgen receptor levels in prostate cancer cells. Int J Oncol. 2016 Oct; 49(4):1609-19.

View in: PubMed

People

Explore

Similar Concepts

Top Journals